PARP inhibition in cancer therapy

TopicLeading institutions, researchers & key papers

This cluster of papers focuses on the use of Poly(ADP-ribose) Polymerase (PARP) inhibitors, such as Olaparib and Niraparib, as a targeted therapy for cancer, particularly in the context of BRCA mutations and DNA repair deficiency. The concept of synthetic lethality, homologous recombination, and the therapeutic potential of PARP inhibitors in various cancers, including platinum-sensitive ovarian cancer, are extensively explored.

247

Works

IDs:OpenAlex

How has PARP inhibition in cancer therapy's publication output changed over time?

ScholarIQpublication output · 2009–2021

Output grew0% over the shown period — from 1 works in 2009 to 1 in 2021.

200920102012201420162017201820192021

What are the most-cited papers on PARP inhibition in cancer therapy?

ScholarIQmost cited works

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono

New England Journal of Medicine. 20093,640 CitationsOPEN ACCESS

Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Kathleen N. Moore, Nicoletta Colombo, Giovanni Scambia, Byoung‐Gie Kim, Ana Oaknin, Michael Friedländer, Alla Lisyanskaya, Anne Floquet, Alexandra Léary, Gabe S. Sonke, Charlie Gourley, Susana Banerjee, Amit M. Oza, Antonio González-Martı́n, Carol Aghajanian, William H. Bradley, Cara Mathews, Joyce F. Liu, Elizabeth Lowe, Ralph Bloomfield, Paul DiSilvestro

New England Journal of Medicine. 20182,881 CitationsOPEN ACCESS

Systematic identification of genomic markers of drug sensitivity in cancer cells

Mathew J. Garnett, Elena J. Edelman, Sonja J. Heidorn, Chris Greenman, Anahita Dastur, King Wai Lau, Patricia Greninger, I. Richard Thompson, Xi Luo, Jorge Soares, Qingsong Liu, Francesco Iorio, Didier Surdez, Li Chen, Randy Milano, Graham R. Bignell, Ah Ting Tam, Helen Davies, Jesse A. Stevenson, Syd Barthorpe, Stephen Lutz, Fiona Kogera, Karl Lawrence, Anne McLaren-Douglas, Xeni Mitropoulos, Tatiana Mironenko, Helen Thi, Laura Richardson, Wenjun Zhou, Frances Jewitt, Tinghu Zhang, Patrick O’Brien, Jessica L. Boisvert, Stacey Price, Wooyoung Hur, Wanjuan Yang, Xianming Deng, Adam P. Butler, Hwan Geun Choi, Jae Won Chang, José Baselga, Ivan Stamenkovic, Jeffrey A. Engelman, Sreenath V. Sharma, Olivier Delattre, Julio Sáez-Rodríguez, Nathanael S. Gray, Jeffrey Settleman, P. Andrew Futreal, Daniel A. Haber, Michael R. Stratton, Sridhar Ramaswamy, Ultan McDermott, Cyril H. Benes

Nature. 20122,599 CitationsOPEN ACCESS

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer

Mansoor R. Mirza, Bradley J. Monk, Jørn Herrstedt, Amit M. Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A. Ledermann, Domenica Lorusso, Ignace Vergote, Noa Ben-Baruch, Christian Marth, Radosław Mądry, René dePont Christensen, Jonathan S. Berek, Anne Dørum, Anna V. Tinker, Andreas du Bois, Antonio González-Martı́n, Philippe Follana, Benedict B. Benigno, Per Rosenberg, Lucy Gilbert, B.J. Rimel, Joseph Buscema, John Balser, Shefali Agarwal, Ursula A. Matulonis

New England Journal of Medicine. 20162,477 CitationsOPEN ACCESS

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

M. William Audeh, James Carmichael, Richard T. Penson, Michael Friedländer, Bethan Powell, Katherine M. Bell‐McGuinn, Clare L. Scott, Jeffrey N. Weitzel, Ana Oaknin, Niklas Loman, Karen H. Lu, Rita K. Schmutzler, Ursula A. Matulonis, Mark Wickens, Andrew Tutt

The Lancet. 20102,292 Citations